缬沙坦对比贝那普利治疗原发性高血压左室肥厚效果的系统评价

发布时间：2019-04-08 08:11

【摘要】：目的:对缬沙坦和贝那普利治疗原发性高血压左心室肥厚效果进行系统评价。方法:使用计算机检索Ovid、Pub Med、MEDLINE、Embase、Cochrane Library、维普(VIP)、中国生物医学文献数据库(CBM)、万方、中国知网(CNKI)等数据库,设置检索时间为从数据库建立至2016年4月。根据Cochrane系统评价方法,筛选出关于缬沙坦对比贝那普利治疗原发性高血压左心室肥厚的中英文随机对照试验(RCT),对纳入的文献进行数据提取和质量评价,运用Rev Man5.2软件进行Meta分析。结果:最终纳入12篇符合条件的随机对照试验。Meta分析结果显示:(1)缬沙坦与贝那普利相比,降低收缩压(MD= 0.86,95%CI= 2.83~1.10,P=0.39)和舒张压(MD=0.48,95%CI= 0.63~1.59,P=0.40)的差异无统计学意义;(2)缬沙坦逆转高血压左心室肥厚效果优于贝那普利[LVMI(MD=2.15,95%CI=0.62~3.70,P=0.006)、LVPWT(MD=0.14,95%CI=0.12~0.16,P0.00001)]。(3)缬沙坦不良反应发生率明显低于贝那普利(OR=0.32,95%CI=0.20~0.51,P0.00001)。结论:与贝那普利相比,缬沙坦治疗高血压左室肥厚效果更好,不良反应更少。
[Abstract]:Objective: to evaluate the efficacy of valsartan and benazepril in the treatment of essential hypertension left ventricular hypertrophy (LVH). Methods: Ovid,Pub Med,MEDLINE,Embase,Cochrane Library, Wip (VIP), Chinese Biomedical Literature Database (CBM), Wanfang and China knowledge Network (CNKI) were searched by computer. The retrieval time was set from the establishment of the database to April 2016. According to Cochrane systematic evaluation method, data extraction and quality evaluation of valsartan versus benazepril in Chinese and English randomized controlled trials (RCT),) on left ventricular hypertrophy in essential hypertension were carried out. Meta analysis was carried out with Rev Man5.2 software. Results: twelve eligible randomized controlled trials were included. Meta-analysis showed that: (1) compared with benazepril, valsartan decreased systolic blood pressure (MD= 0.86, 95% CI = 2.83 / 1.10, P < 0.01). There was no significant difference between MD=0.48,95%CI= 0.39 and DBP (P = 0.63 and 1.59, P = 0.40). (2) valsartan was superior to LVMI (MD=2.15,95%CI=0.62~3.70,P=0.006), LVPWT (MD=0.14,95%CI=0.12~0.16,) in reversing left ventricular hypertrophy in hypertension. (3) the incidence of adverse reactions of valsartan was significantly lower than that of benazepril (OR=0.32,95%CI=0.20~0.51,P0.00001). Conclusion: valsartan is better than benazepril in the treatment of hypertensive left ventricular hypertrophy with fewer adverse reactions.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R544.11

【相似文献】